TB-500 studies and safety
TB-500 is a short fragment of thymosin beta-4. The larger protein’s findings cannot establish the fragment’s benefits or safety.
Actin helps cells change shape and move. Everyday movement is not evidence of a peptide’s effect.
The fragment and the full protein
TB-500 is a synthetic seven-amino-acid fragment based on part of thymosin beta-4, a natural protein with forty-three amino acids. A chemical cap is added to the fragment. The FDA assessment of TB-500 treats it as a different substance from the full protein.
FDA found no published human study of TB-500 in its review. This distinction comes before the encouraging results often described online. Almost all of that work concerns thymosin beta-4. Even a well-designed study of the parent protein cannot tell us that a smaller, chemically modified piece behaves in the same way.
Why actin attracts attention
Actin is a protein involved in cell structure and movement. A structural study of thymosin beta-4 examined how the full protein binds actin. The fragment contains an actin-binding sequence, which helps explain interest in its relationship to tissue repair.
A sequence shared by two molecules does not establish shared clinical effects. Binding in an experimental system, cell movement and recovery after an injury are separate outcomes. FDA also notes that the chemical cap may change how the fragment behaves. The proposed explanation remains incomplete.
What animal studies actually tested
A 2014 stroke experiment in rats tested full-length thymosin beta-4. Some tested amounts improved neurological measures; the highest amount did not show a significant benefit. This was neither a study of TB-500 nor a human recovery trial.
A review of thymosin beta-4 biology covers cell migration, blood-vessel growth and tissue repair. These mechanisms help organize the experimental questions. They do not justify treating every repair finding as a single effect, or assuming that more of a compound produces more benefit.
FDA’s assessment found no animal study establishing healing efficacy for TB-500 itself. That is a gap in the record, rather than proof that the fragment cannot have an effect. Filling the gap requires testing the exact substance, not borrowing a result from its parent.
Human studies of the parent protein
A placebo-controlled safety study in forty healthy volunteers examined intravenous thymosin beta-4. Reported adverse events were infrequent and mild to moderate, with no serious events or dose-limiting toxicity reported. The purpose was early safety and pharmacokinetics: how a substance moves through the body.
The substance was the full protein. Healthy-volunteer tolerability does not establish healing after an injury, and this short study cannot settle long-term safety. Most other human work reviewed by FDA used thymosin beta-4 eye drops or topical gels, again separate preparations and clinical questions.
What is unknown about safety
The absence of human TB-500 studies means there is no reliable side-effect profile, interaction list or established monitoring plan. FDA highlights potential immune responses and peptide-quality concerns. These are reasons for uncertainty, not a measured estimate of how often a particular reaction happens.
The parent protein’s roles in cell migration and blood-vessel growth have raised theoretical cancer questions in preclinical work. No human TB-500 study establishes a cancer risk or rules one out. A mechanism-based concern needs to stay labeled as such.
Community accounts describe recovery, joint comfort, fatigue and local reactions. These are anecdotal, not clinical evidence. They cannot verify the identity of a preparation or establish which ingredient caused a reported change.
Approval, access and sport
TB-500 has no FDA-approved medicine. On the FDA safety-risk page, current as of April 22, 2026, the fragment appears as nominated but withdrawn. The safety concern remains printed beside it. Withdrawal does not provide approval or clearance for compounding.
An online listing and a research-use label do not establish suitability for human use. Clinical evaluation, the legal position of the ingredient and preparation quality are separate issues. No human dosing instructions can be drawn from the studies described here.
TB-500 is prohibited in sport at all times. The 2026 sports-medicine review places recovery claims alongside scarce rigorous human evidence. The comparison page returns to the molecule distinction that is essential to interpreting this literature.